Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 228


Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis.

Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM.

Ecancermedicalscience. 2015 Oct 15;9:582. doi: 10.3332/ecancer.2015.582. eCollection 2015. Review.


Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer.

Bauer J, Ozden O, Akagi N, Carroll T, Principe DR, Staudacher JJ, Spehlmann ME, Eckmann L, Grippo PJ, Jung B.

Mol Cancer. 2015 Oct 24;14(1):182. doi: 10.1186/s12943-015-0456-4.


A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer.

Kumachev A, Yan M, Berry S, Ko YJ, Martinez MC, Shah K, Chan KK.

PLoS One. 2015 Oct 16;10(10):e0140187. doi: 10.1371/journal.pone.0140187. eCollection 2015.


TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.

Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG).

EBioMedicine. 2015 Jun 8;2(8):823-8. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug.


High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.

van den Broek E, Dijkstra MJ, Krijgsman O, Sie D, Haan JC, Traets JJ, van de Wiel MA, Nagtegaal ID, Punt CJ, Carvalho B, Ylstra B, Abeln S, Meijer GA, Fijneman RJ.

PLoS One. 2015 Sep 16;10(9):e0138141. doi: 10.1371/journal.pone.0138141. eCollection 2015.


Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.

Pander J, van Huis-Tanja L, Böhringer S, van der Straaten T, Gelderblom H, Punt C, Guchelaar HJ.

PLoS One. 2015 Jul 29;10(7):e0131091. doi: 10.1371/journal.pone.0131091. eCollection 2015.


Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Carethers JM, Jung BH.

Gastroenterology. 2015 Oct;149(5):1177-1190.e3. doi: 10.1053/j.gastro.2015.06.047. Epub 2015 Jul 26.


Treatment of metastatic colorectal cancer: focus on panitumumab.

Tay RY, Wong R, Hawkes EA.

Cancer Manag Res. 2015 Jun 24;7:189-98. doi: 10.2147/CMAR.S71821. eCollection 2015. Review.


Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.


Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.

Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC.

Br J Cancer. 2015 Jun 30;113(1):37-45.


Standard chemotherapy with cetuximab for treatment of colorectal cancer.

Li XX, Liang L, Huang LY, Cai SJ.

World J Gastroenterol. 2015 Jun 14;21(22):7022-35. doi: 10.3748/wjg.v21.i22.7022.


An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.

Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ.

MAbs. 2015;7(3):494-504. doi: 10.1080/19420862.2015.1022692.


Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365.


EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer.

Venderbosch S, van Lent-van Vliet S, de Haan AF, Ligtenberg MJ, Goossens M, Punt CJ, Koopman M, Nagtegaal ID.

PLoS One. 2015 Apr 17;10(4):e0124538. doi: 10.1371/journal.pone.0124538. eCollection 2015.


GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study.

Cotte E, Villeneuve L, Passot G, Boschetti G, Bin-Dorel S, Francois Y, Glehen O; French Research Group of Rectal Cancer Surgery (GRECCAR).

BMC Cancer. 2015 Feb 12;15:47. doi: 10.1186/s12885-015-1060-0.


VEGF and dual-EGFR inhibition in colorectal cancer.

Falchook GS, Kurzrock R.

Cell Cycle. 2015;14(8):1129-30. doi: 10.1080/15384101.2015.1022071. No abstract available.


Review of systemic therapies for locally advanced and metastatic rectal cancer.

Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A.

J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi: 10.3978/j.issn.2078-6891.2014.112. Review.


Mitochondrial microsatellite instability in patients with metastatic colorectal cancer.

Venderbosch S, van Vliet S, Craenmehr MH, Simmer F, de Haan AF, Punt CJ, Koopman M, Nagtegaal ID.

Virchows Arch. 2015 May;466(5):495-502. doi: 10.1007/s00428-015-1733-8. Epub 2015 Feb 20.


The next steps in next-gen sequencing of cancer genomes.

Hayes DN, Kim WY.

J Clin Invest. 2015 Feb;125(2):462-8. doi: 10.1172/JCI68339. Epub 2015 Feb 2. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk